Lacosamide Tablet, Film Coated
Product Images NDC 0904-7244

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 0904-7244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (C83d2156 4dde 4316 98f1 B3dc751f3eac 00)

Lacosamide Tablets, USP 200 mg film-coated oral tablets in a unit dose package. The label shows the Major Pharmaceuticals brand and includes NDC 0904-7247-68. The package contains 60 tablets and is marked Rx only. It also includes dosing and storage instructions, manufacturer and distributor information.*

FDA Label Image

Carton Label (C83d2156 4dde 4316 98f1 B3dc751f3eac 01)

Lacosamide tablets, USP 150 mg film-coated oral tablets in unit dose packaging by Major Pharmaceuticals. The label highlights that it contains 60 tablets and indicates pharmacist dispensing with a medication guide. It states prescription use only and warns to store between 20°C and 25°C (68°F to 77°F), with allowable excursions. Includes manufacturer and distributor information, lot number LBLN0186-01, and a barcode.*

FDA Label Image

Carton Label (C83d2156 4dde 4316 98f1 B3dc751f3eac 02)

Lacosamide 100 mg film-coated tablets by Major Pharmaceuticals. The label indicates a prescription-only oral tablet in a unit dose format, with 60 tablets per package. It includes storage instructions, dosage caution, and packaging information, featuring the NDC 0904-7245-68 and contact details for Major Pharmaceuticals.*

FDA Label Image

Carton Label (C83d2156 4dde 4316 98f1 B3dc751f3eac 03)

Lacosamide tablets, USP 50 mg, film-coated oral tablets labeled for unit dose. The label includes the labeler Major Pharmaceuticals and specifies 60 tablets per package. It highlights pharmacist instructions to dispense with a medication guide. Storage conditions and warnings are provided. The packaging features the Major Pharmaceuticals logo and NDC 0904-7244-68.*

FDA Label Image

Laco-fig1.jpg (Laco Fig1)

A bar graph showing the median percent reduction in seizure frequency per 28 days from baseline to the maintenance phase by dose in studies 2, 3, and 4. The x-axis lists placebo and various doses of lacosamide (200 mg, 400 mg, 600 mg), with corresponding sample sizes. The y-axis shows seizure reduction percentage from 0% to 45%. The graph indicates higher seizure reductions in lacosamide groups compared to placebo, with statistical significance noted by asterisks.*

FDA Label Image

Laco-fig2.jpg (Laco Fig2)

A line chart titled "Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4." The x-axis represents the percent of patients from 0 to 100, and the y-axis shows responder rate (equal to or greater) ranging from -100% (worsening) to 100% (improvement). The chart compares Placebo (N=359) and Lacosamide at doses of 200 mg/day (N=267), 400 mg/day (N=466), and 600 mg/day (N=202), illustrating patient response rates across these groups.*

FDA Label Image

Laco-str (Laco Str)

Chemical structure of Lacosamide, showing its molecular composition including an amide group, methoxy group, and phenyl ring. The diagram represents the active ingredient Lacosamide as used in the oral film-coated tablet form by Major Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.